Medtronic expanded its reach in the endovascular market with the acquisition of Aptus Endosystems, a company that specializes in advanced technology for endovascular aneurysm repair and thoracic endovascular aneurysm repair.
Medtronic announced that it bought the assets of Aptus for $110 million. It did not disclose other terms of the deal.
Aptus’ products include the Heli-FX EndoAnchor System and Heli-FX Thoracic EndoAnchor System, which complements minimally invasive aneurysm repair by locking an endograft to the aorta or vessel walls. The systems can be used in patients with challenging anatomies and those with complex aortic disease and are compatible with Medtronic’s Endurant and Valiant stent graft systems. Both Heli-FX systems have been cleared by the FDA in the U.S. and have CE mark in Europe.
Aptus also makes the TourGuide Steerable Sheath for delivering peripheral vascular products. The sheath has tip deflection technology for navigating challenging anatomies, which Actus claims reduces the need for using multiple catheters. Medtronic will take over distribution of the sheath in the U.S. and Europe.
Sunnyvale, Calif.-based Actos will join the aortic and peripheral vascular division in Medtronic’s Cardiac and Vascular Group. That group also recently invested in another endovascular technology company with the option to acquire it if milestones are met. The company, AAA Arsenal, develops a foam and delivery catheter for stabilizing aneurysms and reducing the occurrence of endoleaks. Medtronic did not disclose the financial terms of that deal.